
Director of Drug Development, Sarah Cannon Research Institute at Florida Cancer Specialists, Lake Nona @SarahCannonDocs #hncsm #HeadandNeckCancer
Orlando, FL
Joined December 2011
- Tweets17
- Following43
- Followers58
- Likes106
Cesar retweeted
The FDA has granted FTD to CRB-701, a next-generation ADC targeting nectin-4, for patients with recurrent or metastatic HNSCC previously treated with platinum-based chemotherapy and an anti-PD(L)1 therapy.
hubs.li/Q03JRtl90
#hncsm #oncology #cancer
Cesar retweeted
Dr. Cesar Perez presenting at the educational session on Head and neck cancers at ASCO 2024 #ASCO24
Cesar retweeted
Recommendations for Global Curriculum in #MedicalOncology: result of great collaboration btw @myesmo & @ASCO and the full support of @JCOGO_ASCO & @ESMO_Open
The 2023 edition of the ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology is out! Read the paper in @ESMO_Open
📌 ow.ly/nhpq50PZztv
Cesar retweeted
Si la montaña no va a Mahoma, Mahoma va a la montaña. ( If the mountain does not come to Mohammed…)
Visiting our former @SylvesterCancer colleague and friend @CesarAPerezMD in Lake Nona, FL. @FLCancerFound
Cesar retweeted
Replying to @CesarAPerezMD
Cesar retweeted
.@US_FDA granted a fast track designation to KIN-2787 in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma. @CesarAPerezMD @SarahCannonDocs #melcsm
ow.ly/S58P50LtLgL
Cesar retweeted
It's World Cancer Research Day and Dr. Cesar Perez, Director of Drug Development at Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, is sharing his wisdom on the importance of clinical trials in the life of patients facing cancer. #WorldCancerResearchDay
Cesar retweeted
In the phase III JUPITER-02 trial, addition of the anti-PD-1 antibody toripalimab to first-line gemcitabine plus cisplatin for pts with advanced-stage nasopharyngeal carcinoma improved PFS 11.7 vs 8.2 months and also OS (HR 0.61, P = 0.046): nature.com/articles/s41591-0… #hncsm
Cesar retweeted
According to data from a landmark phase 3 trial, in the ITT population of patients with advanced primary SCCHN, the Multikine treatment regimen yielded an OS benefit of 14.1%. #hncsm ow.ly/HoEg50FlLAw
Cesar retweeted
Cabozantinib demonstrates efficacy in radioactive-iodine and VEGFR refractory patients. Another option for thyroid cancer patients but keep in mind the importance of molecular testing to find actionable alterations in NTRK, RET, and BRAF.
thelancet.com/journals/lanon…
Cesar retweeted
#ASCO21 Press Release: JUPITER-02 Trial- Toripalimab plus standard first-line chemo significantly delayed disease progression for pts w recurrent or metastatic nasopharyngeal carcinoma fal.cn/3fQ5G #hncsm #immunoonc
















